



Announcement no. 15/2008

To the NASDAQ OMX Nordic Exchange Copenhagen

Copenhagen, August 27, 2008

## Major shareholder announcement

### *Major shareholder announcement*

Pursuant to section 29 of the Danish Securities Trading Act and section 28a of the Danish Public Companies Act, notice is hereby given that as at August 27, 2008 IPC International PLC, Berkeley, Square House 2<sup>nd</sup> floor, London W1J 6BD, United Kingdom, has changed its shareholding in Curalogic A/S to 11,297,766 shares with a nominal value of DKK 0,50 per share.

IPC International PLC subsequently holds a total of 20.003% of the shares and 20.003% of the votes in Curalogic A/S.

Yours sincerely,

Curalogic A/S

### **For additional information, please contact:**

Peter Moldt, President and CEO, Phone +45 99 99 24 01  
Helle Busck Fensvig, EVP and CFO, Phone +45 99 99 24 03

### **About Curalogic**

Curalogic is a Danish biopharmaceutical company listed on NASDAQ OMX Nordic Exchange Copenhagen (CUR.CO) as a SmallCap+ company. Curalogic has ample cash resources and has demonstrated its ability to conduct complex clinical studies with a small group of development experts. Curalogic has initiated a search process to identify development projects offering an attractive risk profile. Curalogic expects to conclude an agreement during 2008 that will secure future clinical development projects for the Company.

This announcement contains forward-looking statements regarding the Company's future financial development and performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of the Company's knowledge and belief, are reasonable, at this time, but may prove to be erroneous in the future.